BACKGROUND: FOLFIRINOX stands a major breakthrough in the management of metastatic pancreatic adenocarcinoma (MPA). Nonetheless, significant side-effects have been reported using standard FOLFIRINOX. We aimed to compare survival outcomes, response rates and toxicity of patients treated with standard or modified FOLFIRINOX in MPA. METHODS: We included patients aged ≥18 years old, with pathologically confirmed MPA, treated with FOLFIRINOX in the first-line setting. Patients submitted to at least one cycle of full-dose FOLFIRINOX were grouped in the standard FOLFIRINOX group. RESULTS: Patients treated with standard FOLFIRINOX were younger and had less comorbidity. We observed no differences in overall survival or in progression-free survival between the two treatment arms. The only variable independently associated with OS was log10[neutrophil-to-lymphocyte ratio (NLR)]. Modified FOLFIRINOX was associated with a lower dose reduction rate, but a slightly increased incidence of severe toxicity. CONCLUSIONS: Modified FOLFIRINOX presents the same activity against MPA as standard FOLFIRINOX. We found no significant differences in toxicity, possibly due to patient selection and a higher dose reduction rate in the standard FOLFIRINOX arm. NLR stood as an important prognostic marker and further research is needed to comprehend its biological meaning in pancreatic cancer.
BACKGROUND: FOLFIRINOX stands a major breakthrough in the management of metastatic pancreatic adenocarcinoma (MPA). Nonetheless, significant side-effects have been reported using standard FOLFIRINOX. We aimed to compare survival outcomes, response rates and toxicity of patients treated with standard or modified FOLFIRINOX in MPA. METHODS: We included patients aged ≥18 years old, with pathologically confirmed MPA, treated with FOLFIRINOX in the first-line setting. Patients submitted to at least one cycle of full-dose FOLFIRINOX were grouped in the standard FOLFIRINOX group. RESULTS: Patients treated with standard FOLFIRINOX were younger and had less comorbidity. We observed no differences in overall survival or in progression-free survival between the two treatment arms. The only variable independently associated with OS was log10[neutrophil-to-lymphocyte ratio (NLR)]. Modified FOLFIRINOX was associated with a lower dose reduction rate, but a slightly increased incidence of severe toxicity. CONCLUSIONS: Modified FOLFIRINOX presents the same activity against MPA as standard FOLFIRINOX. We found no significant differences in toxicity, possibly due to patient selection and a higher dose reduction rate in the standard FOLFIRINOX arm. NLR stood as an important prognostic marker and further research is needed to comprehend its biological meaning in pancreatic cancer.
Authors: Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux Journal: N Engl J Med Date: 2011-05-12 Impact factor: 91.245
Authors: David Goldstein; Robert Hassan El-Maraghi; Pascal Hammel; Volker Heinemann; Volker Kunzmann; Javier Sastre; Werner Scheithauer; Salvatore Siena; Josep Tabernero; Luis Teixeira; Giampaolo Tortora; Jean-Luc Van Laethem; Rosemary Young; Darryl Neil Penenberg; Brian Lu; Alfredo Romano; Daniel D Von Hoff Journal: J Natl Cancer Inst Date: 2015-01-31 Impact factor: 13.506
Authors: Parvin F Peddi; Sam Lubner; Robert McWilliams; Benjamin R Tan; Joel Picus; Steven M Sorscher; Rama Suresh; A Craig Lockhart; Jian Wang; Christine Menias; Feng Gao; David Linehan; Andrea Wang-Gillam Journal: JOP Date: 2012-09-10
Authors: Derek Weycker; Xiaoyan Li; John Edelsberg; Rich Barron; Alex Kartashov; Hairong Xu; Gary H Lyman Journal: Support Care Cancer Date: 2014-08-01 Impact factor: 3.603
Authors: Daniel D Von Hoff; Thomas Ervin; Francis P Arena; E Gabriela Chiorean; Jeffrey Infante; Malcolm Moore; Thomas Seay; Sergei A Tjulandin; Wen Wee Ma; Mansoor N Saleh; Marion Harris; Michele Reni; Scot Dowden; Daniel Laheru; Nathan Bahary; Ramesh K Ramanathan; Josep Tabernero; Manuel Hidalgo; David Goldstein; Eric Van Cutsem; Xinyu Wei; Jose Iglesias; Markus F Renschler Journal: N Engl J Med Date: 2013-10-16 Impact factor: 91.245
Authors: Victor H F de Jesus; Marcos P G Camandaroba; Vinicius F Calsavara; Rachel P Riechelmann Journal: Ther Adv Med Oncol Date: 2020-02-28 Impact factor: 8.168
Authors: Pietro Carotenuto; Francesco Amato; Andrea Lampis; Colin Rae; Somaieh Hedayat; Maria C Previdi; Domenico Zito; Maya Raj; Vincenza Guzzardo; Francesco Sclafani; Andrea Lanese; Claudia Parisi; Caterina Vicentini; Ian Said-Huntingford; Jens C Hahne; Albert Hallsworth; Vladimir Kirkin; Kate Young; Ruwaida Begum; Andrew Wotherspoon; Kyriakos Kouvelakis; Sergio Xavier Azevedo; Vasiliki Michalarea; Rosie Upstill-Goddard; Sheela Rao; David Watkins; Naureen Starling; Anguraj Sadanandam; David K Chang; Andrew V Biankin; Nigel B Jamieson; Aldo Scarpa; David Cunningham; Ian Chau; Paul Workman; Matteo Fassan; Nicola Valeri; Chiara Braconi Journal: Nat Commun Date: 2021-11-18 Impact factor: 14.919